title: Peripheral blood progenitor cell transplantation: a single centre experience comparing two mobilisation regimens in 67 patients.
abstract: Between June 1991 and January 1995 we performed 67 peripheral blood progenitor cell transplants (PBPCT). Ten patients (group 1) were mobilised with 7 gm/m2 of cyclophosphamide followed by daily G-CSF injections (5 micrograms/kg, subcutaneously). When the white cell count reached 1 x 10(9)/1 they were leukapheresed for 5 days. After stem cell infusion they received G-CSF (10 micrograms/kg/day) until the neutrophil count reached 1.5 x 10(9)/1. Fifty-six patients had PBPCs mobilised with 3 gm/m2 of cyclophosphamide followed by daily subcutaneous G-CSF (5 micrograms/kg) and PBPCs were harvested on 2 consecutive days, when the white cell count rose to 4 x 10(9)/1. After stem cell infusion this group did not receive G-CSF. In 47 of the 56 patients (group 2) adequate MNC (> or = 4 x 10(8)/kg) and/or CFU-GM (> or = 10 x 10(4)/kg) were obtained. Insufficient MNC and/or CFU-GM were obtained in 10 patients. They were therefore transplanted using a combination of bone marrow and peripheral blood progenitor cells (group 3). Overall 64 patients successfully engrafted. Median days to neutrophils > or = 0.5 x 10(9)/1 were 9 (range 8-13), 12 (range 8-25) and 11 (range 9-16) and to platelets > or = 50 x 10(9)/1 were 11 (range 9-23), 13 (range 9-90) and 16 (range 13-99) in groups 1, 2 and 3 respectively. Patients in group 1 had a faster neutrophil recovery than patients in group 2 (P = 0.0002). The three patients who failed to engraft all received a combination of autologous peripheral blood and bone marrow cells.
authors.affiliation: Bone Marrow Transplant Unit, Addenbrooke's NHS Trust, Cambridge, UK.
authors.forename: P
authors.initials: P
authors.lastname: Mahendra
authors.forename: D
authors.initials: D
authors.lastname: Johnson
authors.forename: M A
authors.initials: MA
authors.lastname: Scott
authors.forename: H K
authors.initials: HK
authors.lastname: Jestice
authors.forename: I M
authors.initials: IM
authors.lastname: Hood
authors.forename: S
authors.initials: S
authors.lastname: Ager
authors.forename: G
authors.initials: G
authors.lastname: Bass
authors.forename: P
authors.initials: P
authors.lastname: Barker
authors.forename: P A
authors.initials: PA
authors.lastname: Boraks
authors.forename: D M
authors.initials: DM
authors.lastname: Bloxham
authors.forename: T P
authors.initials: TP
authors.lastname: Baglin
authors.forename: R E
authors.initials: RE
authors.lastname: Marcus
mesh_terms: D000293:Adolescent; D000328:Adult; D000686:Amyloidosis / Q000628:therapy; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D001853:Bone Marrow / Q000187:drug effects*; D002330:Carmustine / Q000008:administration & dosage; D002465:Cell Movement; D003114:Colony-Forming Units Assay; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000494:pharmacology*; D003561:Cytarabine / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage / Q000494:pharmacology*; D019337:Hematologic Neoplasms / Q000188:drug therapy / Q000628:therapy; D018380:Hematopoietic Stem Cell Transplantation; D006412:Hematopoietic Stem Cells / Q000187:drug effects*; D006801:Humans; D007674:Kidney Diseases / Q000628:therapy; D007937:Leukapheresis; D007958:Leukocyte Count; D008297:Male; D008558:Melphalan / Q000008:administration & dosage; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy / Q000628:therapy; D011034:Podophyllotoxin / Q000008:administration & dosage; D012189:Retrospective Studies; D013852:Thiotepa / Q000008:administration & dosage; D019172:Transplantation Conditioning
chemical_list: D003561:Cytarabine; D016179:Granulocyte Colony-Stimulating Factor; D005047:Etoposide; D003520:Cyclophosphamide; D013852:Thiotepa; D011034:Podophyllotoxin; D008558:Melphalan; D002330:Carmustine